J Infect Dis: Intravenous immunoglobulin is safe and effective in treating moderate pneumonia in COVID-19 patients!

Immunoglobulin refers to a small molecule protein produced by human B lymphocytes that can bind antigens or pathogenic bacteria after the body is stimulated by external antigens or pathogenic bacteria
.

It is an important part of human humoral immunity.

B lymphocytes bind antigen or pathogenic bacteria to protect pathogenicity autoimmune diseases

Purpose: Currently, there are no specific drugs for the treatment of COVID-19
.

The therapeutic benefits of intravenous immunoglobulin (IVIG) have been widely proven in diseases

Results: The length of hospital stay in the IVIG group was significantly shorter than that of the SOC group alone (7.
7 days vs.
17.
5 days)
.

Compared with SOC, the time for body temperature, blood oxygen saturation and mechanical ventilation to return to normal in the IVIG group was significantly shorter

Table Primary and secondary efficacy variables (mean ± SD); *The difference is not significant

Table Primary and secondary efficacy variables (mean ± SD); *The difference is not significant

Figure 0-28 Percentage of COVID-19 RT-PCR negative patients

Figure 0-28 Percentage of COVID-19 RT-PCR negative patients

Conclusion: IVIG assisting other antiviral drugs to treat COVID-19 is safe and effective
.

The trial is registered in the Clinical Trials Registry of India (CTRI/2020/06/026222)

IVIG assists other antiviral drugs to treat COVID-19 is safe and effective

Raman RS, Bhagwan Barge V, Anil Kumar D, et al, A Phase II Safety and Efficacy Study on Prognosis of Moderate Pneumonia in Coronavirus Disease 2019 Patients With Regular Intravenous Immunoglobulin Therapy.

A Phase II Safety and Efficacy Study on Prognosis of Moderate Pneumonia in Coronavirus Disease 2019 Patients With Regular Intravenous Immunoglobulin Therapy.
J Leave a message here